Semnur Pharmaceuticals, Inc. (SMNR)

Market Cap	86.56M -96.7%
Revenue (ttm)	n/a
Net Income	-167.68M
EPS	-0.76
Shares Out	230.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,469
Open	0.3660
Previous Close	0.4000
Day's Range	0.3660 - 0.3760
52-Week Range	0.1279 - 23.0000
Beta	-0.03
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About Semnur Pharmaceuticals

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: SMNR

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 22, 2026

Data Sources Report a data error